- Home
- PNBK vs KZIA Comparison
PNBK vs KZIA Comparison
Compare PNBK & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNBK
- KZIA
- Stock Information
- Founded
- PNBK 1999
- KZIA 1994
- Country
- PNBK United States
- KZIA Australia
- Employees
- PNBK N/A
- KZIA N/A
- Industry
- PNBK Major Banks
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- PNBK Finance
- KZIA Health Care
- Exchange
- PNBK Nasdaq
- KZIA Nasdaq
- Market Cap
- PNBK 6.6M
- KZIA 7.8M
- IPO Year
- PNBK N/A
- KZIA 1999
- Fundamental
- Price
- PNBK $1.80
- KZIA $1.42
- Analyst Decision
- PNBK
- KZIA Strong Buy
- Analyst Count
- PNBK 0
- KZIA 1
- Target Price
- PNBK N/A
- KZIA $20.00
- AVG Volume (30 Days)
- PNBK 16.8K
- KZIA 116.4K
- Earning Date
- PNBK 11-19-2024
- KZIA 11-15-2024
- Dividend Yield
- PNBK N/A
- KZIA N/A
- EPS Growth
- PNBK N/A
- KZIA N/A
- EPS
- PNBK N/A
- KZIA N/A
- Revenue
- PNBK $27,300,000.00
- KZIA $1,655,324.00
- Revenue This Year
- PNBK N/A
- KZIA $806.89
- Revenue Next Year
- PNBK N/A
- KZIA N/A
- P/E Ratio
- PNBK N/A
- KZIA N/A
- Revenue Growth
- PNBK 3.61
- KZIA 248000.00
- 52 Week Low
- PNBK $1.38
- KZIA $1.39
- 52 Week High
- PNBK $4.70
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- PNBK 46.33
- KZIA 20.74
- Support Level
- PNBK $1.81
- KZIA $1.42
- Resistance Level
- PNBK $1.78
- KZIA $1.89
- Average True Range (ATR)
- PNBK 0.13
- KZIA 0.24
- MACD
- PNBK -0.02
- KZIA 0.02
- Stochastic Oscillator
- PNBK 52.38
- KZIA 1.40
About PNBK Patriot National Bancorp Inc.
Patriot National Bancorp Inc provides consumer and commercial banking services to individuals, small and medium-sized businesses, professionals, and municipalities in Fairfield and New Haven Counties in Connecticut and Westchester County, New York. Its products include checking accounts, savings accounts, money market accounts, time certificates of deposit, and individual retirement accounts. The Bank's lending portfolio is comprised of commercial mortgage and construction loans, commercial loans, home improvement loans, home equity lines of credit, and other personal loans. In addition, the Bank offers bank checks, money orders, automated teller machines, interactive teller machines, online and mobile banking, credit cards, and debit cards.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.